Does Your Home Harbor a Killer?
“HIGH POINT, N.C., Jan. 28, 2025 /PRNewswire/ — January is Radon Action Month, a vital time for individuals and communities to learn about radon risks and take action. This week, designated as National Radon Awareness Week by the CDC, the Lung Cancer Action Network (LungCAN) urges everyone to test their homes for radon and reduce exposure to this silent threat.”
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
“Key Takeaways: Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager, achieved a 35.3% ORR and 20.3 months median overall survival in trials.”
Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC
“Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting.”
Clean energy is key to reducing lung cancer deaths
“As an oncologist, I can’t forget some of my patients’ stories. One of those belongs to a mother of two I diagnosed at age 35 with non-small cell lung cancer. She was a physician and a long-distance runner who had never smoked a day in her life. She died of metastatic lung cancer about two years after her diagnosis.”
A community-based approach to address lung cancer screening disparities in the black community using the Witness Project® framework: development and pilot trial
“Disparities in lung cancer outcomes persist among Black Americans, necessitating targeted interventions to address screening inequities. This paper reports the development and refinement of Witness Project® Lung, a community-based initiative tailored to the specific needs of the Black community, aiming to improve awareness and engagement with lung cancer screening.”
PD-1, PD-L1-Targeting Agent Shows Promise in Treatment of Patients with Non–Small Cell Lung Cancer
“Key Takeaways: NSCLC accounts for 87% of lung cancer cases, with only 25%-30% of patients responding to treatment, necessitating advanced therapies. Immune checkpoint inhibitors, including bsAbs, have improved outcomes by offering targeted treatments with enhanced safety profiles.”
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
“TOKYO & BASKING RIDGE, N.J., January 31, 2025–(BUSINESS WIRE)–The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant DATROWAY® (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy versus standard of care in patients with stage 1 adenocarcinoma non-small cell lung cancer (NSCLC) after complete surgical resection who are ctDNA-positive or have other high risk pathological features.”
Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer
“Key Takeaways: No further fractionation studies are needed for LS-SCLC radiotherapy; focus shifts to adaptive therapy and FLASH radiotherapy for improved outcomes. SCLC incidence is declining, with a more balanced gender distribution; updated staging criteria are crucial for radiotherapy candidacy.”
Video:
